Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of bortezomib plus FLAG-IDA followed by bortezomib monotherapy in relapsed or refractory acute myeloid leukemia
2005-004370-24Phase 2Active
- Sponsor
- Dr. Jesús San Miguel Izquierdo
- Start
- Dec 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, fludarabine, cytarabine and idarubicin in acute myeloid leukemia (AML), sponsored by Dr. Jesús San Miguel Izquierdo. Primary endpoint: Overall response rate. Started Dec 2005; status: active.
02
Drugs
bortezomibfludarabinecytarabineidarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2005-004370-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004370-24.